Combination of Calcium Hydroxyapatite and Autologous Blood for Endoscopic Treatment of Vesicoureteral Reflux in Children

Overview

Journal Int Urol Nephrol

Publisher Springer

Specialty Nephrology

Date 2014 Feb 21

PMID 24554218

Citations 2

Authors

Roozbeh Tanhaeivash

Abdol-Mohammad Kajbafzadeh

Atefeh Zeinoddini

Neda Khalili

Mona Vahidi Rad

Reza Heidari

Affiliations

Soon will be listed here.

Abstract

Objective: To report the results of endoscopic correction of vesicoureteral reflux (VUR) with concomitant injection of pure calcium hydroxyapatite (CaHA) and autologous blood.

Patients And Methods: Records of patients who underwent endoscopic correction of VUR using concomitant injection of CaHA and autologous blood from 2008 through 2010 were retrospectively reviewed. Data regarding patients' demographics, preoperative VUR grades, febrile urinary tract infections, complications of procedure, postoperative VUR grades and cure rates were collected. Voiding cystourethrography was performed 3 months postoperatively.

Results: Total number of 23 children (9 girls and 14 boys) with 40 refluxing ureters were included. The mean age of children was 1.9 ± 0.97 (SD) years. Reflux grades were II to IV in 14, 11 and 15 renal refluxing units (RRUs), respectively. The mean follow-up period was 44 months. VUR was successfully treated in 87.5% of RRUs after three injections. Significant statistical difference was found between VUR grades before and after the first, second and third injections (p < 0.001, p = 0.001 and p = 0.011, respectively). Moreover, there was a significant difference between primary reflux grade and treatment success (p = 0.031). Febrile UTI was resolved in 85% of patients (17 of 20 patients with febrile UTI) after endoscopic treatment which shows significant improvement (p < 0.001). The procedure was uneventful in all patients, and no obstruction was reported during the follow-up period.

Conclusion: Concomitant injection of pure CaHA without any additives (hyaluronic acid, etc.) and autologous blood can be an effective, repeatable and cost-benefit approach for the management of children suffering VUR with a success rate of 87.5% after three injections.

Citing Articles

Application of urethral injection of calcium hydroxyapatite as a natural bulking agent for improvement of urinary incontinence in children with spinal dysraphism.

Kamran H, Tafazoli N, Eftekharzadeh S, Samaei M, Kajbafzadeh A Int Urol Nephrol. 2023; 55(6):1403-1411.

PMID: 37085677 DOI: 10.1007/s11255-023-03596-z.

Pelvic floor electromyography and urine flow patterns in children with vesicoureteral reflux and lower urinary tract symptoms.

Sharifi-Rad L, Ladi-Seyedian S, Amirzargar H, Kajbafzadeh A Int Braz J Urol. 2018; 44(6):1207-1214.

PMID: 30325607 PMC: 6442192. DOI: 10.1590/S1677-5538.IBJU.2018.0401.

References

Kershen R, Atala A . New advances in injectable therapies for the treatment of incontinence and vesicoureteral reflux. Urol Clin North Am. 1999; 26(1):81-94, viii. DOI: 10.1016/s0094-0143(99)80008-1. View

Alizadeh F, Mazdak H, Khorrami M, Khalighinejad P, Shoureshi P . Postoperative ureteral obstruction after endoscopic treatment of vesicoureteral reflux with polyacrylate polyalcohol copolymer (Vantris®). J Pediatr Urol. 2012; 9(4):488-92. DOI: 10.1016/j.jpurol.2012.11.007. View

Chertin B, Puri P . Endoscopic management of vesicoureteral reflux: does it stand the test of time?. Eur Urol. 2002; 42(6):598-606; discussion 606. DOI: 10.1016/s0302-2838(02)00447-5. View

Kajbafzadeh A, Habibi Z, Tajik P . Endoscopic subureteral urocol injection for the treatment of vesicoureteral reflux. J Urol. 2006; 175(4):1480-3. DOI: 10.1016/S0022-5347(05)00675-0. View

Eryildirim B, Tarhan F, Kuyumcuoglu U, Erbay E, Faydaci G . Endoscopic subureteral injection treatment with calcium hydroxylapatite in primary vesicoureteral reflux. Int Urol Nephrol. 2006; 39(2):417-20. DOI: 10.1007/s11255-006-9011-y. View

Caldamone A, Diamond D . Long-term results of the endoscopic correction of vesicoureteral reflux in children using autologous chondrocytes. J Urol. 2001; 165(6 Pt 2):2224-7. DOI: 10.1016/S0022-5347(05)66170-8. View

Mayer R, Lightfoot M, Jung I . Preliminary evaluation of calcium hydroxylapatite as a transurethral bulking agent for stress urinary incontinence. Urology. 2001; 57(3):434-8. DOI: 10.1016/s0090-4295(00)01098-0. View

Tarcan T, Tinay I, Temiz Y, Simsek F . Long-term results of endoscopic treatment of vesicoureteral reflux with the sub-ureteric injection of calcium hydroxyapatite. Int Urol Nephrol. 2007; 39(4):1011-4. DOI: 10.1007/s11255-007-9222-x. View

Chertin B, Kocherov S . Long-term results of endoscopic treatment of vesicoureteric reflux with different tissue-augmenting substances. J Pediatr Urol. 2009; 6(3):251-6. DOI: 10.1016/j.jpurol.2009.10.011. View

10.

Puri P, Chertin B, Velayudham M, Dass L, Colhoun E . Treatment of vesicoureteral reflux by endoscopic injection of dextranomer/hyaluronic Acid copolymer: preliminary results. J Urol. 2003; 170(4 Pt 2):1541-4. DOI: 10.1097/01.ju.0000083924.44779.80. View

11.

Bakhtiari J, Kajbafzadeh A, Marjani M, Veshkini A, Tavakoli A, Gharagozlou M . Endoscopic treatment of vesicoureteral reflux using calcium hydroxyl apatite in dogs. BMC Res Notes. 2011; 4:14. PMC: 3037325. DOI: 10.1186/1756-0500-4-14. View

12.

Al-Hunayan A, Kehinde E, Elsalam M, Al-Mukhtar R . Outcome of endoscopic treatment for vesicoureteral reflux in children using polydimethylsiloxane. J Urol. 2002; 168(5):2181-3. DOI: 10.1016/S0022-5347(05)64349-2. View

13.

Trsinar B, Cotic D, Oblak C . Possible causes of unsuccessful endoscopic collagen treatment of vesicoureteric reflux in children. Eur Urol. 1999; 36(6):635-9. DOI: 10.1159/000020059. View

14.

Kirsch A, Hensle T, Scherz H, Koyle M . Injection therapy: advancing the treatment of vesicoureteral reflux. J Pediatr Urol. 2008; 2(6):539-44. DOI: 10.1016/j.jpurol.2005.12.004. View

15.

Cho E, Kang S, Park H, Cho Y, Lee Y, Kim J . Submucosal injection of poly(lactic-co-glycolic acid) microspheres in rabbit bladder as a potential treatment for urinary incontinence and vesicoureteral reflux: preliminary results. J Biomater Sci Polym Ed. 2005; 16(9):1109-20. DOI: 10.1163/1568562054798509. View

16.

Lackgren G, Wahlin N, Skoldenberg E, Stenberg A . Long-term followup of children treated with dextranomer/hyaluronic acid copolymer for vesicoureteral reflux. J Urol. 2001; 166(5):1887-92. DOI: 10.1016/s0022-5347(05)65713-8. View

17.

Sorensen M, Koyle M, Cowan C, Zamilpa I, Shnorhavorian M, Lendvay T . Injection volumes of dextranomer/hyaluronic acid are increasing in the endoscopic management of vesicoureteral reflux. Pediatr Surg Int. 2010; 26(5):509-13. DOI: 10.1007/s00383-010-2558-9. View

18.

Ormaechea M, Ruiz E, Denes E, Gimenez F, Denes F, Moldes J . New tissue bulking agent (polyacrylate polyalcohol) for treating vesicoureteral reflux: preliminary results in children. J Urol. 2009; 183(2):714-7. DOI: 10.1016/j.juro.2009.10.047. View

19.

Ramseyer P, Meagher-Villemure K, Burki M, Frey P . (Poly)acrylonitrile-based hydrogel as a therapeutic bulking agent in urology. Biomaterials. 2006; 28(6):1185-90. DOI: 10.1016/j.biomaterials.2006.09.019. View

20.

Leonard M, Decter A, Hills K, Mix L . Endoscopic subureteral collagen injection: are immunological concerns justified?. J Urol. 1998; 160(3 Pt 2):1012-6. View